Liver Cancers

From Mechanisms to Management
 
 
Springer (Verlag)
  • erschienen im November 2018
 
  • Buch
  • |
  • Hardcover
  • |
  • XVI, 312 Seiten
978-3-319-92215-7 (ISBN)
 

This book explores in detail the primary liver cancers of hepatocellular carcinoma and cholangiocarcinoma examining the pathogenesis of disease along with diagnosis and current management options together with exploration of future treatment strategies and areas of controversy. Furthermore, the book highlights management of the common secondary malignancies and touches on benign liver tumours and how to best manage these.

Written in a clear and didactic style, this volume includes summaries of the key learning points and questions so that the reader can gauge their knowledge and understanding.

This book is aimed to broaden the knowledge base of primary care physicians, general physicians along with specialists in hepatology, oncology and hepato-biliary surgery

1st ed. 2019
  • Englisch
  • Cham
  • |
  • Schweiz
Springer International Publishing
  • Für Beruf und Forschung
  • 34 farbige Abbildungen, 12 s/w Abbildungen
  • |
  • 80 schwarz-weiße und 100 farbige Abbildungen, Bibliographie
  • Höhe: 246 mm
  • |
  • Breite: 164 mm
  • |
  • Dicke: 19 mm
  • 742 gr
978-3-319-92215-7 (9783319922157)
10.1007/978-3-319-92216-4
weitere Ausgaben werden ermittelt

Dr Tim Cross, BMedSci (Hons), MB BS, MD, FRCP

Dr Cross qualified from St. Bartholomew's hospital medical college in 1996. He undertook general gastroenterology training in North East London and hepatology training at Addenbrookes hospital, Cambridge, The Royal Free Hospital, University College Hospital and Kings College Hospital, London. He was a consultant at the South West Liver Unit, Plymouth UK before moving to the Royal Liverpool Hospital in 2012.

Prof Daniel Palmer, BSc (Hons), MBChB, PhD, FRCP

Professor Palmer graduated from the University of Birmingham in 1995 and undertook his specialist training in Medical Oncology in the Birmingham Oncology Centre before taking the position of Cancer Research UK Clinician Scientist and Senior Lecturer, University of Liverpool. He took the North West Cancer Research Chair of Medical Oncology at the University of Liverpool in 2011. His specialist interests include development of novel therapies and clinical trials for hepatobiliary and pancreatic cancers.

Part I: Hepatocellular carcinoma (HCC).- Pathogenesis of HCC).- Surveillance for HCC.- Diagnosis of HCC.- Part II: Treatment.- Surgery.- Ablation techniques.- Transarterial chemoembolization.- Transarterial Radio-embolization.- Liver transplantation.- Chemotherapy and HCC.- Emerging novel therapies.- Part IIV: Cholangiocarcinoma.- Pathogenesis.- Diagnosis and surveillance.- Part IV:Management.- Surgery.- Ablation and embolic treatments.- Chemotherapy.- Emerging novel therapies.- Mixed Malignancies HCC/cholangiocarcinoma.- Part V: Metastatic Liver cancers.- Colorectal cancer.- Melanoma.- Neuroendocrine tumours.- Sarcomas.- Lymphoma.- Part VI: Benign Liver Tumours.- Benign Liver tumours.
This book explores in detail the primary liver cancers of hepatocellular carcinoma and cholangiocarcinoma examining the pathogenesis of disease along with diagnosis and current management options together with exploration of future treatment strategies and areas of controversy. Furthermore, the book also highlights management of the common secondary malignancies and touches on benign liver tumours and how to best manage these.

Written in a clear and didactic style, this volume includes summaries of the key learning points and questions so that the reader can gauge their knowledge and understanding.

This book is aimed to broaden the knowledge base of primary care physicians, general physicians along with specialists in hepatology, oncology and hepato-biliary surgery
DNB DDC Sachgruppen

Sofort lieferbar

128,39 €
inkl. 7% MwSt.
in den Warenkorb